In prostate cancer cells, the androgen receptor (AR) promoter was shown to be an epigenetic target of PRMT5, and knockdown of PRMT5 caused a reduction in H4R3me2 marks at the AR promoter and a subsequent reduction in AR expression (42). This evidence concerns the gene AR and prostate carcinoma.